계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
AdvanCell
company
About
AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
- Sydney,New South Wales,Australia
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $18M
- Industries
- Biotechnology,Clinical Trials,Pharmaceutical
- Founded date
- Jan 1, 2019
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Legal Name
- AdvanCell Isotopes Pty Ltd.
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$18M $2.10M
AdvanCell has raised a total of
$18M $2.10M
in funding over 2 rounds. Their latest funding was raised on
Aug 23, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 23, 2022 | Series B | $18M | 1 |
Morningside Venture Investments
|
— | Detail |
| Dec 23, 2021 | Grant | $2.10M | 1 |
NSW Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
AdvanCell is funded by 2 investors.
Morningside Venture Investments
and NSW Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Morningside Venture Investments
|
Yes | Series B |
|
NSW Health
|
Yes | Grant |
Employee Profiles
Number of Employee Profiles
1
AdvanCell has 1 current employee profiles, including
Board member Anthony Aiudi
Board member
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
